One thousand patients have now been prescribed Althea medicinal cannabis products in Australia, which are attracting an average of 11 new patients a day.
Althea Group Holdings, a licensed producer and supplier of pharmaceutical grade medicinal cannabis, says the milestone achievement represents more than a 53 per cent increase on the 651 patients reported on April 29, 2019.
The company says it welcomed 227 new patients in May and is now averaging more than 11 new patients every business day.
The milestone was claimed to be achieved five months ahead of the company’s previously stated goal of having its products prescribed to 1,000 patients by November 2019.
There are also currently 185 Australian healthcare professionals (HCPs) who have prescribed Althea’s products, with the company expecting to increase the number of Althea prescribers to 200, by month’s end.
The rapid uptake of Althea’s products is being driven by the company’s strategy comprising a medical science liaison team and Althea Concierge, the company’s proprietary web-based platform, which is said to greatly reduce application times for HCPs looking to prescribe medicinal cannabis.
“With our on-the-ground team and unique Althea Concierge platform, Althea is able to educate HCPs about the benefits of our products and streamline the entire medicinal cannabis prescription process,” Althea CEO and Managing Director Josh Fegan said.
The company recently announced the launch of Althea Concierge UK, describing the market as an emerging one with significant potential, including an estimated treatable population of up to 2.9 million patients.
